HK1220703A1 - 改進的β胸腺素片段 - Google Patents

改進的β胸腺素片段

Info

Publication number
HK1220703A1
HK1220703A1 HK16108739.1A HK16108739A HK1220703A1 HK 1220703 A1 HK1220703 A1 HK 1220703A1 HK 16108739 A HK16108739 A HK 16108739A HK 1220703 A1 HK1220703 A1 HK 1220703A1
Authority
HK
Hong Kong
Prior art keywords
improved beta
beta thymosin
fragments
thymosin fragments
improved
Prior art date
Application number
HK16108739.1A
Other languages
English (en)
Inventor
大衛．克羅克福德
克里斯蒂安．
．艾倫
加布里埃爾．索斯恩
Original Assignee
Regenerx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals Inc filed Critical Regenerx Biopharmaceuticals Inc
Publication of HK1220703A1 publication Critical patent/HK1220703A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK16108739.1A 2008-03-17 2016-07-21 改進的β胸腺素片段 HK1220703A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3720708P 2008-03-17 2008-03-17
US8379808P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
HK1220703A1 true HK1220703A1 (zh) 2017-05-12

Family

ID=41417312

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108739.1A HK1220703A1 (zh) 2008-03-17 2016-07-21 改進的β胸腺素片段

Country Status (9)

Country Link
US (3) US20110172155A1 (zh)
EP (2) EP2260106A4 (zh)
JP (1) JP2011514383A (zh)
CN (2) CN102037133B (zh)
AU (1) AU2009258034B2 (zh)
CA (1) CA2718774A1 (zh)
HK (1) HK1220703A1 (zh)
MX (1) MX2010010177A (zh)
WO (1) WO2009151689A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593120B1 (en) * 2010-07-14 2017-03-08 Adistem Ltd Thymosin beta peptides for use in the treatment of hiv or aids
WO2014078787A1 (en) 2012-11-19 2014-05-22 Wellstat Therapeutics Corporation Stem cell mobilization and tissue repair and regeneration
FR3070857B1 (fr) * 2017-09-11 2019-09-06 Centre Scientifique De Monaco Utilisation de la scleritine en tant qu'agent protecteur de cellules contre des agents toxiques
CU24626B1 (es) * 2019-12-26 2022-11-07 Centro Nac De Biopreparados Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
CN1058500C (zh) * 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α－1衍生物
WO2006023910A2 (en) * 2004-08-20 2006-03-02 The University Of Texas Southwestern Medical Center At Dallas Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
PT1335743E (pt) * 2000-11-02 2010-03-29 Regenerx Biopharmaceuticals Inibição ou reversão do envelhecimento da pele por meio de péptidos sequestrando actina
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
CN1241636C (zh) * 2001-05-17 2006-02-15 雷金纳克斯生物制药公司 用胸腺素β4治疗大疱性表皮松解症
US9056087B2 (en) * 2001-08-29 2015-06-16 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
TWI353849B (en) * 2002-01-25 2011-12-11 Us Gov Health & Human Serv Methods and compositions for the promotion of hair
AU2003296875B2 (en) * 2002-02-06 2008-01-24 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003223601A1 (en) * 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
KR20060013368A (ko) * 2003-03-31 2006-02-09 리지너크스 바이오 파마소티컬스, 인코포레이티드 티모신 베타 4, 유사물질, 이소폼, 및 다른 유도체들을전달하기 위한 조성물 및 방법
MXPA06000517A (es) * 2003-07-18 2006-07-10 Regenerx Biopharmaceuticals Composiciones y metodos para el tratamiento o prevencion de dano debido a la exposicion a radiacion.
DE10357951A1 (de) * 2003-12-11 2005-07-07 Emitec Gesellschaft Für Emissionstechnologie Mbh Wabenkörper mit mindestens einem platzsparenden Messfühler, sowie entsprechende Lambdasonde
KR20070094849A (ko) * 2005-01-13 2007-09-21 리지너크스 바이오 파마소티컬스, 인코포레이티드 신경-, 근육- 또는 신경-근육-퇴행성 질병으로 인한 조직악화, 부상 또는 손상을 치료하거나 또는 예방하거나 또는상기 질병에 의해 불리한 영향을 받는 조직을 회복하는방법
CA2593198A1 (en) * 2005-01-14 2006-07-20 Regenerx Biopharmaceuticals, Inc. Modified beta thymosin peptides
JP2008542265A (ja) * 2005-05-27 2008-11-27 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 細胞核に侵入する組成物
JP2008543877A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
EP1913013A2 (en) * 2005-07-19 2008-04-23 Grannus Biosciences Truncated oxidized thymosin beta4 and derivatives thereof
AU2006272612B2 (en) * 2005-07-26 2011-10-06 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2007001206A1 (fr) * 2005-07-27 2007-01-04 Gaman Vadim Anatolievich Systeme d'information client-serveur et procede permettant d'obtenir une interface graphique
WO2007084544A2 (en) * 2006-01-17 2007-07-26 Regenerx Biopharmaceuticals, Inc. Methods of treating or preventing tissue damage caused by increased blood flow
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
EP2076277A4 (en) * 2006-10-06 2011-06-01 Regenerx Biopharmaceuticals A METHOD FOR TREATING OR PREVENTING DETERIORATION, DAMAGE OR TISSUE DAMAGE DUE TO ORAL MUCOSAL DISEASE OR DISORDER AND / OR REGULATING NF-KAPPAB FALL OR REMOVING NF-KAPPAB ASSISTED ACTIONS

Also Published As

Publication number Publication date
EP2260106A4 (en) 2011-04-20
US20150203561A1 (en) 2015-07-23
US20130196912A1 (en) 2013-08-01
JP2011514383A (ja) 2011-05-06
CA2718774A1 (en) 2009-12-17
AU2009258034B2 (en) 2015-07-16
MX2010010177A (es) 2012-08-23
EP2811030A2 (en) 2014-12-10
CN102037133B (zh) 2016-01-13
AU2009258034A1 (en) 2009-12-17
CN102037133A (zh) 2011-04-27
WO2009151689A2 (en) 2009-12-17
CN105504043B (zh) 2020-01-31
WO2009151689A9 (en) 2010-05-20
EP2260106A1 (en) 2010-12-15
CN105504043A (zh) 2016-04-20
US20110172155A1 (en) 2011-07-14
EP2811030A3 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
ZA200906495B (en) Klotho beta
GB201020970D0 (en) Early entry
HK1152470A1 (zh) 治療β-澱粉樣變性病的多肽
EP2170745A4 (en) ACCELERATION AND OUTPUT TRANSPORT BELT
HK1134806A1 (en) Hopper structure
GB2451357B (en) Ceramic Armour
GB0921999D0 (en) Early entry
GB0820950D0 (en) Funnel
GB201003729D0 (en) Bat
EP2249646A4 (en) PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
HK1155334A1 (zh) 梳子
EP2201180A4 (en) CLAMP
GB0722995D0 (en) Completion arrangement
EP2348042A4 (en) AMYLOID PEPTIDE BETA MODIFIED
HK1220703A1 (zh) 改進的β胸腺素片段
IL207352A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
GB0922083D0 (en) Early entry
IL207351A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
GB0920030D0 (en) Early entry
IL207346A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
GB0723387D0 (en) Improved dehumldifier
PL1950770T3 (pl) Izolator
GB0715213D0 (en) Igf-1
PL2148344T3 (pl) Mikroprzełącznik
EP2249830A4 (en) DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY